Skip to main content Accessibility help
  • Print publication year: 2015
  • Online publication date: November 2015

26 - Management of cancer of the body of the uterus

Related content

Powered by UNSILO
Aalders, J., Abeler, V., Kolstad, P., et al. (1980). Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathological study of 540 patients. Obstet. Gynecol., 56, 419–427.
Abeler, V. M. and Kjorstad, K. E. (1991). Endometrial adenocarcinoma in Norway. A study of a total population. Cancer, 67, 3093–3103.
Akram, T., Maseelall, P. and Fanning, J. (2005). Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am. J. Obstet. Gynecol., 192, 1365–1367.
Amant, F., Cadron, I., Fuso, L., et al. (2005a). Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol. Oncol., 98, 274–280.
Amant, F., Moerman, P., Neven, P., et al. (2005b). Endometrial cancer. Lancet, 366, 491–505.
Ambros, R. A., Sherman, M. E., Zahn, C. M., et al. (1995). Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumours displaying serous differentiation. Hum. Pathol., 26, 1260–1267.
Andreyev, H. J., Benton, B., Lalji, A., et al. (2013). Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial. Lancet, 382, 2084–2092.
Benedet, J. L., Bender, H., Jones, H. 3rd, et al. (2000). FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int. J. Gynecol. Obstet., 70, 209–262.
Blake, P., Swart, A., Orton, J., et al. (2009). Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review,and meta-analysis.Lancet; 373, 137–146.
Board of the Faculty of Clinical Oncology, The Royal College of Radiologists. (2006). Radiotherapy Dose-Fractionation. London: Royal College of Radiologists, p. 36.
Bokhman, J. V. (1983). Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol., 15, 10–17.
Colombo, N., Preti, E., Landoni, F., et al. (2013). Endometrial cancer: ESMO clinical practice guidelines. Ann. Oncol., 24, vi33–vi38.
Creutzberg, C. L., van Putten, W. L., Koper, P. C., et al. (2000). Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet, 355, 1404–1411.
Creutzberg, C. L., van Putten, W. L., Koper, P. C., et al. (2003). Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol. Oncol., 89, 201–209.
Creutzberg, C. L., Nout, R. A., Lybeert, M. L., et al. (2011). Fifteen year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 81, e631–638.
Dhar, K. K., NeedhiRajan, T., Koslowski, M., et al. (2005). Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol. Oncol., 97, 924–927.
Eifel, P., Hendrickson, M., Ross, J., et al. (1982). Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. Cancer, 50, 163–170.
ESTRO. (2002). The GEC ESTRO Handbook of Brachytherapy, ed. Gerbaulet, A., Potter, R., Mazeron, J.-J., et al. Brussels: ESTRO, Chapter 15, pp. 365–401.
FIGO. (2009). FIGO staging for uterine sarcomas. Int. J. Gynecol. Obstet., 104, 179.
Fiorica, J. V., Brunetto, V. L., Hanjani, P., et al. (2004). Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol, Oncol., 92, 10–14.
Galaal, K., Bryant, A., Fisher, A., et al. (2012). Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev. 2012 Sep 12;9:CD006655.
Gredmark, T., Kvint, S., Havel, G., et al. (1995). Histopathological findings in women with postmenopausal bleeding. Br. J. Obstet. Gynaecol., 102, 133–136.
Gupta, J. K., Chien, P. F., Voit, D., et al. (2002). Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet. Gynecol. Scand., 81, 799–816.
Hensley, M. L., Maki, R., Venkatraman, E., et al. (2002). Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J. Clin. Oncol., 20, 2824–2831.
Hogberg, T. (2008). Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials. Clin. Oncol. (R. Coll. Radiol.), 20, 463–469.
Jones, D. A. and Stout, R. (1986). Results of intracavitary radium treatment for adenocarcinoma of the body of the uterus. Clin. Radiol., 37, 169–171.
Johnson, N., Bryant, M., Miles, T., et al. (2011). Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst. Rev. doi: 10.1002/14651858.CD003175.pub2
Kanjeekal, S., Chambers, A., Fung, M. F., et al. (2005). Systemic therapy for advanced uterine sarcomas: a systematic review of the literature. Gynecol. Oncol., 97, 624–637.
Keys, H. M., Roberts, J. A., Brunetto, V. L., et al. (2004). A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol., 92, 744–751.
Kieser, K. and Oza, A. M. (2005). What's new in systemic therapy for endometrial cancer. Curr. Opin. Oncol., 17, 500–504.
Kim, S. H., Kim, H. D., Song, Y. S., et al. (1995). Detection of deep myometrial invasion in endometrial carcinoma: comparison of transvaginal ultrasound, CT and MRI.J. Comput. Assist. Tomogr., 19, 766–772.
Kitchener, H., Blake, P., Sanderock, J., Parmer, M., ASTEC Study Group. (2009). Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study, Lancet; 373, 125–136.
Kokka, F., Brockbank, E., Oram, D., et al. (2010). Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst. Rev., 12, CD007926.
Kong, A., Johnson, N., Kitchener, H. C., et al. (2012). Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J. Natl Cancer Inst., 104, 1625–1634.
Kurman, R. J., Kaminski, P. F. and Norris, H. J. (1985). The behaviour of endometrial hyperplasia. A long-term study of ‘untreated’ hyperplasia in 170 patients. Cancer, 56, 403–412.
Lai, C. H. and Huang, H. J. (2006). The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr. Opin. Obstet. Gynecol., 18, 29–34.
Lewin, S., Herzog, T., Medel, N., et al. (2010). Comparative performance of the 2009 International Federation of Gynecology and Obstetrics’ staging system for uterine corpus cancer. Obstet. Gynecol., 116, 1141–1149.
Livi, L., Andreopoulou, E., Shah, N., et al. (2004). Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1988. Clin. Oncol. (R. Coll. Radiol.), 16, 261–268.
Maggi, R., Lissoni, A., Spina, M., et al. (2006). Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br. J. Cancer, 95, 266–271.
Martin-Hirsch, P. L., Lilford, R. J. and Jarvis, G. J. (1996). Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analysis of published randomised controlled trials. Eur. J. Obstet. Gynecol. Reprod. Biol., 65, 201–207.
Michener, C. M., Peterson, G., Kulp, B., et al. (2005). Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J. Cancer Res. Clin. Oncol., 131, 581–584.
Montz, F. J., Bristow, R. E., Bovicelli, A., et al. (2002). Intrauterine progesterone treatment of early endometrial cancer. Am. J. Obstet. Gynecol., 186, 651–657.
Nag, S., Erickson, B., Parikh, S., et al. (2000). The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int. J. Radiat. Oncol. Biol. Phys., 48, 779–790.
NICE. (2007). Heavy Menstrual Bleeding NICE Clinical Guideline 44.London: National Institute for Health and Care Excellence.
NICE. (2015). Suspected cancer: recognition and referral. NICE guideline. London: National Institute for Health and Care Excellence.
Niwa, K., Tagami, K., Lian, Z., et al. (2005). Outcome of fertility-preserving treatment in young women with endometrial carcinomas. Br. J. Obstet. Gynecol., 112, 317–320.
Nordal, R. N., Kjørstad, K. E., Stenwigh, A. E., et al. (1993). Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976–1985. Int. J. Gynecol. Cancer, 3, 110–115.
Nout, R. A., Smit, V. T., Putter, H., et al. (2010). Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet, 375, 816–823.
Oza, A. M., Elit, L. and Tsao, M. (2011). Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group. J.Clin. Oncol., 29, 3278–3285.
Park., J. Y., Kim, D. Y., Kim, T. J., et al. (2013a). Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet. Gynecol., 122, 7–14.
Park, H., Nam, E., Sunghoon, K., et al. (2013b). The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol., 170, 39–44.
Pecorelli, S., et al., FIGO Committee on Gynecologic Oncology. (2009). Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynecol. Obstet., 105, 103–104.
Reed, N. S. (2008). The management of uterine sarcomas. Clin. Oncol. (R Coll Radiol.), 20, 470–478.
Reed, N.S., Mangioni, C., Malmström, H., et al. (2008). Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur. J. Cancer, 44, 808–818.
Schouten, L. J., Goldbohm, R. A. and van den Brandt, P. A. (2004). Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J. Natl Cancer Inst., 96, 1635–1638.
Small, W., Mell, L., Anderson, P., et al. (2008). Consensus guidelines for the delineation of the clinical target volume for intensity modulated pelvic radiotherapy in the postoperative treatment of endometrial and cervical cancer. Int. J. Radiat. Oncol. Biol. Phys., 71, 428–434.
Tsoref, D. and Oza, A. (2011). Recent advances in systemic therapy for advanced endometrial cancer. Curr. Opin. Oncol., 23, 494–500.
Whitney, C. W., Brunetto, M. F., Homesley, H. D., et al. (2004). Phase II study of medroxy-progesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol., 92, 4–9.
WHO classification. (2003). In World Health Organization Classification of Tumours: Pathology and genetics of tumours of the breast and female genital organs, ed. Tavassoli, A. and Devilee, P.. Lyon: IARC Press, Chapter 4.